











Eligibility			Administration					
Approval Status	Year of First Approval	Approved Population	Administration & Dosing	Location	Yearly Follow-up Schedule			
One product that is widely approved 	2017	 All ages with and without inhibitors	 1-4x/MONTH	 Home or Treatment Center	1-2 Times per year and as needed			
One product in phase 3 								
Efficacy								
Median Annual Bleed Rate	% With Zero Bleeds	Factor Level (approximate representations of factor half-life)						
<1.5 median for all bleeds, regardless of whether the bleed was treated, spontaneous, or traumatic	40-50% percentage with zero bleeds regardless of whether the bleed was treated, spontaneous, or traumatic							
Factor levels will not change, but the effect is similar to having mild hemophilia								
Safety Considerations	Potential Safety Risks		Psychosocial Burden					
Adverse Reactions	Hypersensitivity Reactions	Inhibitors	Seeking a Hemophilia Free Mind					
The most common adverse reactions are injection site reactions, headache, and joint pain			 <ul style="list-style-type: none"> ● Daily concerns ● Occasional concerns ● Little to no concerns 	<ul style="list-style-type: none"> ● Travel ● Employment/ education ● Injection schedule ● Medication ● Physical activity 	<ul style="list-style-type: none"> ● Treatment efficacy ● Bleeding risk ● Joint pain ● Blood-borne infections (HCV/HIV) ● Affected family members and carriers 			
	Thrombotic Events	Elevated Liver Enzymes						
	<1% *Occurred in patients receiving at least one dose of activated prothrombin complex concentrate (aPCC)							

Data was sourced from the FDA, EMA, and Health Canada prescribing information and applicable and published Phase 3 clinical studies.
 Last Update: March 2024.

Modified from Krumb & Hermans; "Living with a "hemophilia-free mind" - the new ambition of hemophilia care?"; 2021